Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06480591 · ClinicalTrials.gov registry record
Evaluation of the Pathobiology of CALR-mutated MPN Cells
A clinical trial of Myeloproliferative Neoplasm, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 35
- Enrollment target
- 2
- Study locations
NCT06480591 is a study of Myeloproliferative Neoplasm that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 35 participants, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (58% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06480591, a study of Myeloproliferative Neoplasm, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
Conditions Studied
Interventions
- OTHER Blood Draw
Study Locations (2)
North Carolina
- Atrium Health Levine Cancer - Charlotte
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2026-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06480591
The ClinicalTrials.gov registry entry for NCT06480591 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 40 other Myeloproliferative Neoplasm trials with a reported enrollment target (58% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myeloproliferative Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT06480591 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06480591 about?
NCT06480591 is a clinical study titled "Evaluation of the Pathobiology of CALR-mutated MPN Cells". The purpose of this study is to understand why there is a greater risk of thrombosis in patients who have the JAK2 mutation as compared to those with CALR mutations.
What is the current status of trial NCT06480591?
This trial is currently recruiting. The enrollment target is 35 participants. The study started on 2025-01-21. Estimated completion is 2026-09.
What conditions does trial NCT06480591 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasm.
What interventions are being tested in trial NCT06480591?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT06480591?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06480591 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
RECRUITING · Phase 2
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RECRUITING
-
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.